Identifying quantitative evidence-based parameters to monitor emerging resistance to new antibiotics

por Arieti, F, Garlasco, J, Magrini, E, Tebon, M, Compri, M, Babu Rajendran, N, Pezzani, M D, Tacconelli, E
Publicado 2023

Immunotherapy with low-dose recombinant interleukin 2 after high-dose chemotherapy and autologous stem cell transplantation in neuroblastoma.

por Pession, A., Prete, A., Locatelli, F., Pierinelli, S., Pession, A. L., Maccario, R., Magrini, E., De Bernardi, B., Paolucci, P., Paolucci, G.
Publicado 1998

Phase II trial of carboplatin and etoposide for patients with recurrent high-grade glioma

por Franceschi, E, Cavallo, G, Scopece, L, Paioli, A, Pession, A, Magrini, E, Conforti, R, Palmerini, E, Bartolini, S, Rimondini, S, Esposti, R Degli, Crinò, L
Publicado 2004

Gefitinib in patients with progressive high-grade gliomas: a multicentre phase II study by Gruppo Italiano Cooperativo di Neuro-Oncologia (GICNO)

por Franceschi, E, Cavallo, G, Lonardi, S, Magrini, E, Tosoni, A, Grosso, D, Scopece, L, Blatt, V, Urbini, B, Pession, A, Tallini, G, Crinò, L, Brandes, A A
Publicado 2007

HER3 genomic gain and sensitivity to gefitinib in advanced non-small-cell lung cancer patients

por Cappuzzo, F, Toschi, L, Domenichini, I, Bartolini, S, Ceresoli, G L, Rossi, E, Ludovini, V, Cancellieri, A, Magrini, E, Bemis, L, Franklin, W A, Crino, L, Bunn, P A, Hirsch, F R, Varella-Garcia, M
Publicado 2005